Calidi Biotherapeutics Inc (AMEX:CLDI)’s traded shares stood at 0.54 million during the latest session, with the company’s beta value hitting 0.60. At the last check today, the stock’s price was $0.79, to imply a decrease of -5.95% or -$0.05 in intraday trading. The CLDI share’s 52-week high remains $29.30, putting it -3608.86% down since that peak but still an impressive -1.27% since price per share fell to its 52-week low of $0.80. The company has a valuation of $6.38M, with an average of 0.26 million shares in intraday trading volume over the past 10 days and average of 157.72K shares over the past 3 months.
Calidi Biotherapeutics Inc (AMEX:CLDI) trade information
After registering a -5.95% downside in the latest session, Calidi Biotherapeutics Inc (CLDI) has traded red over the past five days. The 5-day price performance for the stock is -35.25%, and -34.71% over 30 days. With these gigs, the year-to-date price performance is -94.77%. Short interest in Calidi Biotherapeutics Inc (AMEX:CLDI) saw shorts transact 0.16 million shares and set a 2.46 days time to cover.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The extremes give us $2 and $9 for target low and target high price respectively. As such, CLDI has been trading -1039.24% off suggested target high and -153.16% from its likely low.
Calidi Biotherapeutics Inc (CLDI) estimates and forecasts
Looking at statistics comparing Calidi Biotherapeutics Inc share performance against respective industry, we note that the company has outperformed competitors. Calidi Biotherapeutics Inc (CLDI) shares are -50.84% down over the last 6 months, with its year-to-date growth rate higher than industry average at 74.68% against 17.50%. Revenue is forecast to grow 39.30% this quarter before jumping 92.10% for the next one.
CLDI Dividends
Calidi Biotherapeutics Inc has its next earnings report out on 2024-Aug-13. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
Calidi Biotherapeutics Inc (AMEX:CLDI)’s Major holders
Calidi Biotherapeutics Inc insiders hold 22.78% of total outstanding shares, with institutional holders owning 3.01% of the shares at 3.90% float percentage. In total, 3.01% institutions holds shares in the company.
We also have Fidelity Extended Market Index Fund and Brinker Capital Destinations Tr-Destinations Multi Strategy Alt Fd as the top two Mutual Funds with the largest holdings of the Calidi Biotherapeutics Inc (CLDI) shares. Going by data provided on Aug 31, 2024, Fidelity Extended Market Index Fund holds roughly 17.81 shares. This is just over 0.16% of the total shares, with a market valuation of $13879.0. Data from the same date shows that the other fund manager holds a little less at 7.03, or 0.06% of the shares, all valued at about 5483.0.
